GlaxoSmithKline Pharmaceuticals Limited has announced the resignation of Dr. Simrat Sohal from the position of Compliance Officer and Senior Management Personnel. The resignation is effective from the close of business hours on August 5, 2026, as she intends to pursue opportunities outside the organization. Consequently, she will cease to be a Senior Management Personnel of the company effective the said date.

The company informed the stock exchanges regarding this change in senior managerial personnel in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was also made in accordance with SEBI Circular Nos. CIR/CFD/CMD/412015 dated September 9, 2015 and Exchange Circular List/Comp/14/2018-19 dated June 20, 2018.

Resignation Details

The filing provided specific particulars regarding the cessation of Dr. Sohal's role within the company. The reason for the change was cited as a resignation to pursue external opportunities.

Dr. Simrat Sohal had submitted her resignation notice on May 19, 2026, confirming her final working day as August 5, 2026. She expressed her commitment to ensuring a smooth transition and completing all handover responsibilities during her notice period. The acceptance of the resignation was confirmed by the company management.

GlaxoSmithKline Pharmaceuticals held its Q4 FY2026 and Full Year Earnings Call on May 13, 2026, with Managing Director Bhushan Akshikar and Chief Financial Officer Ronojit Biswas presenting the results to analysts and institutional investors. The meeting was conducted digitally and the transcript was uploaded to the company's investor relations page pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The outcome disclosure was signed by Ajay Nadkarni, Vice President – Administration, Real Estate & Company Secretary, on May 18, 2026.

Full Year Financial Performance

For the full year, GlaxoSmithKline Pharmaceuticals delivered profitable growth with meaningful margin expansion. The company crossed a significant milestone, recording its first-ever Profit After Tax (PAT) excluding exceptionals of more than INR1,000 crores. Key financial metrics for the full year are summarised below:

CFO Ronojit Biswas noted that top-line growth was muted due to disruption at a key Contract Manufacturing Organisation (CMO) following a fire, which largely impacted the general medicines portfolio. Despite this, promoted brands delivered competitive external performance and the company gained market share.

Q4 Standalone Performance

For the standalone quarter, sales were up 2%, EBITDA grew 5%, and PAT growth was at 6%. EBITDA margin for the quarter improved by 1 percentage point to 35%, supported by better gross margins and cost management. Management noted that headline sales were muted due to lingering supply constraints and delayed vaccine shipments, which are expected to shift into the June quarter.

Management indicated that supply constraints shaved off approximately 3% to 3.5% of top-line growth for the quarter, with part of the impact attributed to phasing of vaccine consignments that arrived in March but could not be cleared by regulatory agencies in time, spilling over into Q1 of the new financial year.

Business Segment Highlights

Across its three business pillars — General Medicines (GenMed), Vaccines, and Specialty — performance was mixed but broadly in line with management expectations.

General Medicines: The GenMed portfolio remained broadly flat for FY2026, with supply constraints accounting for a loss of more than INR100 crores in revenue. Promoted brands such as Augmentin and Calpol grew 3 to 4 percentage points ahead of the market. Tail-end and distributed brands, including Eltroxin, saw softer demand. Management estimated that underlying GenMed growth, adjusting for supply disruptions, would have been in the range of 3% to 4%.

Vaccines: The vaccines portfolio delivered blended double-digit growth in excess of 11% to 12% for FY2026. Pediatric vaccines were up 9%, maintaining market leadership in the private vaccines segment. The adult vaccine Shingrix continued strong prescription growth, with management pivoting to a new cardiovascular metabolic strategy leveraging the linkage between cardiovascular metabolic disease and herpes prevention.

Specialty: The specialty portfolio, comprising the respiratory products Trelegy Ellipta and Nucala, and oncology assets Zejula (ovarian cancer) and Jemperli (endometrial cancer), grew significantly on a smaller base. The innovative portfolio now contributes approximately 6% of top-line sales, up from approximately 2% on a like-for-like basis. Nucala has been clocking more than 100 to 120 new patients per month. Trelegy Ellipta has maintained and grown patient share and market share despite 8 to 10 generic versions being launched over the past approximately 10 months.

Pipeline and New Launches

GlaxoSmithKline Pharmaceuticals highlighted a robust pipeline with 26 ongoing clinical trials, including 14 studies in India. Key pipeline and launch updates include:

Management noted that for multiple myeloma, India has approximately 18,000 new cases annually, with a prevalence of approximately 40,000 to 45,000 patients at any given time. The launch lag for Blenrep between the US and India has been reduced to approximately 6 to 8 months.

Margin Expansion and Cost Management

CFO Ronojit Biswas outlined three key levers that drove gross margin improvement: a conscious shift in portfolio mix away from price-controlled products, competitive pricing in line with peers, and active cost-of-goods reduction for NLEM products through sourcing changes and forward contracts. SG&A efficiencies were driven by field force productivity improvements and AI-led optimisation. EBITDA margins have improved from approximately 24% four years ago to 34% for the full year and 35% for the current quarter.

Management noted that approximately 40% of the business remains covered under the National List of Essential Medicines (NLEM). On pricing, management stated that agreements are in place to protect against raw material and packaging material cost volatility for the next 12 to 18 months. The company's stated priority is top-line growth, with a focus on maintaining current margin levels while reinvesting in new launches and innovative therapies.

Outlook and Strategic Priorities

Management reaffirmed the ambition of double-digit top-line growth, supported by the resolution of supply constraints, the ramp-up of the innovative portfolio, and multiple planned launches in the coming financial year. Key strategic priorities include driving top-line growth, accelerating the launch of innovative medicines and vaccines with reduced launch lag, and embedding GenAI and digital ways of working to improve efficiency across the value chain. Management guided that the GenMed business should return to growth in the range of 6% to 8%, and the vaccines business should deliver strong high-double-digit numbers in the coming financial year.